Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Smoking Cessation 1Rectal Neoplasms 1Prostatic Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hematuria 1Fatigue 1Carcinoma, Transitional Cell 1

Interventions

Oxaliplatin 290Capecitabine 206Fluorouracil 181Cisplatin 168Docetaxel 138S 1 (combination) 132Paclitaxel 121Leucovorin 116Irinotecan 106pembrolizumab 103Trastuzumab 72apatinib 56Nivolumab 56sintilimab 45Drug Therapy 43Surgical Procedures, Operative 37Radiotherapy 37Bevacizumab 37Ramucirumab 34titanium silicide 31Hyperthermic Intraperitoneal Chemotherapy 30Epirubicin 30Carboplatin 30tislelizumab 28Cyclophosphamide 27XELOX 24Tegafur 23Folfox protocol 22Albumin-Bound Paclitaxel 22camrelizumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Stomach Neoplasms × Urinalysis × Clear all
NCT00580281 2013-10-24

Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors

Memorial Sloan Kettering Cancer Center

Phase NA Completed
33 enrolled
GastrointestinalMyeloidOther hematologic neoplasm

Leukemia, Stomach Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡